A greater proportion of drug tests conducted in Stage 3 (4.5%, n=40) returned 'positive' results than in Stage 1 (1.3%, n=91) or Stage 2 (1.8%, 126). In Stage 1, cannabis and buprenorphine were the most commonly detected non-prescribed drugs (36.3% and 16.5% respectively).
In Stage 2, morphine (27.8%) was the most commonly detected drug, followed by failure or refusal to supply a sample or returning a very dilute sample (23.0%). In Stage 3, morphine (35.0%) and buprenorphine (30.0%) were the most commonly detected drugs.
There was a downward trend in the proportion of participants who felt 'sure' that they needed help to keep from relapsing to drug use over the program, although this only reached significance between baseline and the end of Stage 2 (n = 39).
A downward trend in the proportion of participants who felt 'sure' that they needed help to keep from taking part in further criminal acts or behavior was also apparent; this trend was only significant from baseline to the end of Stage 2 (n = 39).
The vast majority of participants were 'sure' they wanted to attend the program, 'sure' that the CDTP would be helpful to them and satisfied with most aspects of the CDTP.
The programmatic aspects that the majority of participants did not like were the number of drug tests, non-contact 'box' visits (visits where the offender and the visitor cannot make contact with one another) and the possibility of being regressed from a later stage to an earlier stage (e.g. for non-admitted drug use).
When asked for open-ended comments about the program, participants were largely positive about the program, although some participants made negative comments and suggestions for change regarding box visits, sanctions and employment.